So today we had a session on diversity equity inclusion in hematology at the British Society of Haematology and I gave a talk on diversity equity inclusion in clinical trials in Europe. The reason why this is important is first of all, of course, because having a diverse population in a trial also means that you get results on pharmacokinetics and pharmacodynamics on different populations and also that you will get a population, a patient population in your trial that matches the later patient population that is going to use, for example, intervention, for example, a drug...
So today we had a session on diversity equity inclusion in hematology at the British Society of Haematology and I gave a talk on diversity equity inclusion in clinical trials in Europe. The reason why this is important is first of all, of course, because having a diverse population in a trial also means that you get results on pharmacokinetics and pharmacodynamics on different populations and also that you will get a population, a patient population in your trial that matches the later patient population that is going to use, for example, intervention, for example, a drug. So, these are obvious important reasons from a scientific background but also because there is such a difference in access to new medicines across Europe, it’s also important that the trials are recruiting patients from all of Europe and from different parts of countries from rural and urban areas because it can be quite a long time between access or approval of a drug until you have access in a country, if you have access, if it’s reimbursed. So, during this period, it’s only through trials the patient can gain access to new treatments that are sometimes quite effective. So, this is another reason for striving for a diverse and inclusive trial environment.
